NewNWS newsroom live◌Local weatherLocating…--°H --° · L --°Thursday 19 November 2026--:--:--AEDT · Sydney
NewNWSThe Global DeskThe world, in sharper focus.
Live wire
Business · Global desk · Single-source report

Oral Wegovy tablets approved for Australian market

The Therapeutic Goods Administration has cleared Wegovy GLP-1 pills for sale, marking the first time the weight-loss medication will be available in tablet form rather than injection in Australia.

· Published · 2 min read
Novo Nordisk in Mainz
Archive photograph: Novo Nordisk in Mainz Photo: ManuelB701 Licence: CC0 Source ↗ Licence details ↗

The story

The Therapeutic Goods Administration (TGA) has granted approval for the manufacture and retail sale of Wegovy GLP-1 tablets in Australia, making the drug the first oral weight-loss treatment to be offered locally. Retailers say the pills will be stocked in pharmacies from Friday, expanding options that previously consisted only of injectable formulations such as Wegovy, Ozempic and Mounjaro.

Michael Wright, president of the Royal Australian College of General Practitioners (RACGP), emphasized that patients should consult their general practitioners before starting the medication. Wright described the tablet as a small-molecule medication that is better absorbed orally than peptide-based injections, adding that GLP-1 agonists are generally well tolerated but not suitable for everyone.

The Wegovy tablet contains the same active GLP-1 ingredient as the injectable version but is taken on an empty stomach each morning with a small amount of water. Health officials note that the oral format may improve accessibility for some users, although the cost of the product remains a concern for many Australians.

A closer look

The federal government has indicated interest in listing GLP-1 drugs on the Pharmaceutical Benefits Scheme (PBS) to reduce out-of-pocket expenses. Health Minister Mark Butler previously said that subsidies would target individuals with established cardiovascular disease and a high body-mass index, pending agreements with manufacturers.

Novo Nordisk, the maker of Wegovy, already supplies the tablet in the United States and the United Kingdom. Australian approval follows those markets, and the government’s push for PBS listing reflects broader efforts to make newer weight-loss therapies more affordable for eligible patients.


Single-source report

This report presents the named publisher’s account and has not yet been independently corroborated.